Industry / South Korea
Boehringer Ingelheim Outpaces OTC Competitors
August 2008 | Company Finance AlertBoehringer Ingleheim is outpacing the South Korean over-the-counter (OTC) medicine sector. The German company's sales increased 1.9% in the first half of 2008, while most other competitors experienced a downturn in revenue. Growth in South Korean OTC sales also exceeded that posted by Boehringer Ingleheim's global consumer healthcare division (+1.6%). BMI believes that one of the key reasons behind this strong performance is firm's enlightened marketing
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
